Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.

Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.

Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.

Join us for a quick audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.

Japanese major presses on with post-Shire divestments even after passing strategic target.

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of developments in the global biopharmaceutical industry.